Anixa Biosciences, Inc.
ANIX · NASDAQ
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Market Cap | $99,377 | $89,844 | $93,371 | $111,643 |
| - Cash | $1,495 | $1,910 | $1,053 | $1,271 |
| + Debt | $213 | $221 | $230 | $232 |
| Enterprise Value | $98,095 | $88,155 | $92,548 | $110,604 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$9 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2,436 | -$2,994 | -$3,386 | -$3,154 |
| % Margin | – | – | – | – |
| Net Income | $0 | -$2,790 | -$3,184 | -$2,883 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.07 | -0.087 | -0.1 | 0.3 |
| % Growth | 19.2% | 13.4% | -133.3% | – |
| Operating Cash Flow | -$1,511 | -$1,503 | -$2,904 | -$927 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1,511 | -$1,503 | -$2,904 | -$927 |